Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Dyadic International Q3 2026 Results: Net Loss of $1.36M, Loss Narrows

Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.

Watch the Dyadic International Inc earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.41.2
Net income-1.4-2.0
EPS (diluted, $ a share)$-0.04$-0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-61.4%
Operating margin-403.6%
Source

10-Q filed with the SEC, NASDAQ: DYAI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Dyadic International Inc: key numbers

Share price
$0.3200Close, Nov 16
Market cap
$12.8M
Shares outstanding
40.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dyadic International Inc

All →
11:57 AM ET 8-K
Financial Results

Dyadic International Financial Results

Dyadic International reported Q3 2026 financial results, highlighting its first direct commercial protein sales and expanded OEM distribution through IBT Bioservices. The company reported a net loss of $1.5M on revenue of $0.7M as it shifts focus toward larger strategic partnerships and licensing arrangements for its C1 and Dapibus production platforms.

Term
Q3 2026

“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”

Joe Hazelton, President and Chief Operating Officer

“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”

Joe Hazelton, President and Chief Operating Officer
5:28 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Dyadic International Nasdaq/NYSE Compliance Notice

Dyadic International received two deficiency notices from Nasdaq for failing to maintain a minimum bid price of $1.00 per share and a minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance with both requirements.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.